| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -200,099 | -170,126 |
| Depreciation and amortization | 505 | 349 |
| Stock-based compensation | 23,109 | 13,812 |
| Issuance of pik interest debt | 3,479 | 2,300 |
| Accrued interest on revenue interest financing liability | 20,290 | 15,491 |
| Amortization of debt discount | 2,205 | 1,430 |
| Inventory reserve | 819 | 819 |
| Other | -4,340 | -3,131 |
| Prepaid expenses and other current assets | -7,638 | -6,246 |
| Accounts receivable, net | 16,992 | 12,458 |
| Accounts payable and accrued expenses | 6,530 | 5,416 |
| Accrued interest | 53 | 43 |
| Operating right-of-use assets and lease liabilities | 132 | 66 |
| Inventory | 13,783 | 14,178 |
| Net cash used in operating activities | -161,774 | -147,659 |
| Cash paid for property and equipment | 142 | 115 |
| Net cash used in investing activities | -142 | -115 |
| Proceeds from issuance of common stock from exercise of stock options | 373 | 80 |
| Net proceeds from issuance of debt | 0 | 0 |
| Net proceeds from underwritten public offering | 0 | - |
| Payment of employee tax obligations related to vesting of performance stock units | -564 | - |
| Net cash (used in) provided by financing activities | -191 | 80 |
| Net decrease in cash and cash equivalents and restricted cash | -162,107 | -147,694 |
| Cash and cash equivalents at beginning of period | 300,125 | - |
| Cash and cash equivalents at end of period | 138,018 | - |
Phathom Pharmaceuticals, Inc. (PHAT)
Phathom Pharmaceuticals, Inc. (PHAT)